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Imaging dose in breast radiotherapy: does breast size affect the dose to the
organs at risk and the risk of secondary cancer to the contralateral breast?
Abstract
Correct target positioning is crucial for accurate dose delivery in breast radiotherapy resulting in utilisation of
daily imaging. However, the radiation dose from daily imaging is associated with increased probability of
secondary induced cancer. The aim of this study was to quantify doses associated with three imaging
modalities and investigate the correlation of dose and varying breast size in breast radiotherapy. Methods:
Planning computed tomography (CT) data sets of 30 breast cancer patients were utilised to simulate the dose
received by various organs from a megavoltage computed tomography (MV-CT), megavoltage electronic
portal image (MV-EPI) and megavoltage cone-beam computed tomography (MV-CBCT). The mean dose to
organs adjacent to the target volume (contralateral breast, lungs, spinal cord and heart) were analysed. Pearson
correlation analysis was performed to determine the relationship between imaging dose and primary breast
volume and the lifetime attributable risk (LAR) of induced secondary cancer was calculated for the
contralateral breast. Results: The highest contralateral breast mean dose was from the MV-CBCT (1.79 Gy),
followed by MV-EPI (0.22 Gy) and MV-CT (0.11 Gy). A similar trend was found for all organs at risk (OAR)
analysed. The primary breast volume inversely correlated with the contralateral breast dose for all three
imaging modalities. As the primary breast volume increases, the likelihood of a patient developing a radiation-
induced secondary cancer to the contralateral breast decreases. MV-CBCT showed a stronger relationship
between breast size and LAR of developing a radiation-induced contralateral breast cancer in comparison with
the MV-CT and MV-EPI. Conclusions: For breast patients, imaging dose to OAR depends on imaging
modality and treated breast size. When considering the use of imaging during breast radiotherapy, the
patient's breast size and contralateral breast dose should be taken into account.
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Abstract
Introduction: Correct target positioning is crucial for accurate dose delivery in
breast radiotherapy resulting in utilisation of daily imaging. However, the
radiation dose from daily imaging is associated with increased probability of
secondary induced cancer. The aim of this study was to quantify doses
associated with three imaging modalities and investigate the correlation of dose
and varying breast size in breast radiotherapy. Methods: Planning computed
tomography (CT) data sets of 30 breast cancer patients were utilised to
simulate the dose received by various organs from a megavoltage computed
tomography (MV-CT), megavoltage electronic portal image (MV-EPI) and
megavoltage cone-beam computed tomography (MV-CBCT). The mean dose to
organs adjacent to the target volume (contralateral breast, lungs, spinal cord
and heart) were analysed. Pearson correlation analysis was performed to
determine the relationship between imaging dose and primary breast volume
and the lifetime attributable risk (LAR) of induced secondary cancer was
calculated for the contralateral breast. Results: The highest contralateral breast
mean dose was from the MV-CBCT (1.79 Gy), followed by MV-EPI (0.22 Gy)
and MV-CT (0.11 Gy). A similar trend was found for all organs at risk (OAR)
analysed. The primary breast volume inversely correlated with the contralateral
breast dose for all three imaging modalities. As the primary breast volume
increases, the likelihood of a patient developing a radiation-induced secondary
cancer to the contralateral breast decreases. MV-CBCT showed a stronger
relationship between breast size and LAR of developing a radiation-induced
contralateral breast cancer in comparison with the MV-CT and MV-EPI.
Conclusions: For breast patients, imaging dose to OAR depends on imaging
modality and treated breast size. When considering the use of imaging during
breast radiotherapy, the patient’s breast size and contralateral breast dose
should be taken into account.
Introduction
Volumetric anatomical images have become routine in
image-guided radiotherapy (IGRT) for a number of
tumour sites, as they provide three-dimensional soft
tissue information. Daily volumetric imaging has been
shown to be effective in reducing systematic and random
uncertainties in patient positioning for various tumour
sites1–3 and improved dose delivery.4,5 Volumetric
imaging may offer additional information to improve the
32 ª 2015 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of
Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and
no modifications or adaptations are made.
setup accuracy in breast radiotherapy;6–8 however, daily
imaging with ionising radiation can increase the dose to
organs at risk (OAR) significantly,9–11 potentially
increasing the patients’ likelihood of developing a
secondary cancer.12
Numerous studies have reported the dose to OAR from
various image guidance procedures.9,10,13–16 A weak
correlation between body mass index (BMI) and imaging
dose was determined for megavoltage cone-beam CT
(MV-CBCT) imaging of the pelvis, chest and intracranial
region.15 However, the relationship, if any, between breast
size and imaging dose has not been investigated.
During breast radiotherapy, two-dimensional
orthogonal electronic portal imaging (EPI) has
traditionally been used to verify patient setup.17 However,
for complex breast radiotherapy techniques such as
partial breast irradiation, EPI has been found to be
inadequate.7,8 This is attributed to the EPI providing
limited soft tissue information, requiring surrogate
structures such as bony landmarks or implanted radio-
opaque markers to acquire positional information of the
target volume. Currently, three-dimensional computed
tomography (CT) imaging within the treatment room is
becoming more available with various vendors providing
different options, including the MV-CBCT available on
Siemens linear accelerators (Siemens Medical Solutions,
Erlangen, Germany) and the helical megavoltage CT
(MV-CT) available on Tomotherapy units (Accuray Inc.,
Sunnyvale, CA).
The dose and Biological Effects of Ionising Radiation
(BEIR VII) lifetime attributable risk (LAR) for standard
and complex breast radiotherapy treatments with
kilovoltage cone-beam CT imaging was recently
investigated.18 BEIR VII provides comprehensive risk
estimates for cancer and other health effects from
exposure to ionising radiation. In this study, the increased
risk of developing secondary cancer in the contralateral
breast due to MV imaging modalities, compared to that
associated with treatment alone, is evaluated using the
BEIR VII model.19 The aim of this study was to compare
the dose received by OAR from the MV-CT, MV-EPI and
MV-CBCT with consistent imaging parameters for each
modality in patients with varying breast sizes.
Materials and Methods
Patient data sets
Thirty patient data sets were retrospectively evaluated for
this study. These patients previously underwent breast
radiotherapy between April 2010 and May 2011. Patients
were treated in the supine position (14 left sided and 16
right sided) after breast conservation surgery. Patients
were selected consecutively until 30 cases were accrued.
Approval for the study was granted by South Western
Sydney Human Research Ethics Committee in August
2011, and the study was conducted from September 2011
to February 2012.
The treatment planning CT data sets were acquired on
a Siemens Somatom Sensation 4 (Siemens Medical
Solutions, Germany) with 0.25 cm slice thickness.
Delineation of the breasts, heart, lungs and spinal cord
was completed by a senior radiation therapist with Focal
v4.40 (Elekta AB, Stockholm, Sweden) and checked by a
radiation oncologist. All delineation was completed
according to the predetermined breast and heart
delineation protocols.20,21
Imaging dose
The XiO treatment planning system (Elekta AB,
Stockholm, Sweden) was utilised to simulate and estimate
the radiation dose from the orthogonal MV-EPI and MV-
CBCT. A prototype Tomotherapy planning station
(Accuray Inc., Sunnyvale, CA) was used to simulate and
estimate the dose from a MV-CT using TomoDirect
pattern.
The MV-CT technique used a 3.5 MV beam and a
predefined scan selection of normal (pitch of 2). The scan
range/length was adjusted according to breast size with
1 cm margin superiorly and inferiorly. For the orthogonal
MV-EPI, an anterior–posterior (0°) and a lateral field
(270° and 90° for right and left breast respectively) were
created with a 6 MV beam, each with varying field sizes
according to the patient’s breast size, and a beam-on time
of 2 and 3 monitor units (MU) respectively. The MV-EPI
fields were delivered to the isocentre. The MV-CBCT was
created with a 6 MV, 200° beam arc, with a standard
field width of 27.4 cm and field length adjusted for
individual patients according to their breast size with
1 cm margin. The rotational beam began at 270°, rotating
200° clockwise to finish at 110°, and was divided into 200
subfields at 1° intervals. The MV-CBCT was centred on
the midline to avoid gantry–couch collisions and an 8
MU protocol was used as this is the minimum deliverable
MU.
To assess the overall significance of daily imaging (25
scans) for each image modality, the OAR dose from the
patient’s original tangential wedged breast radiotherapy
plan was calculated. For each patient, mean OAR dose
was recorded for the three imaging modalities and the
radiotherapy plan. Using SPSS software (IBM SPSS
Statistics for Windows, Version 20.0.; IBM Corp.,
Armonk, NY), a Pearson correlation analysis was
performed to determine the relationship between imaging
dose, primary breast volume and BMI for all OAR.
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Secondary cancer risk
The LAR of developing radiation-induced contralateral
breast cancer was estimated using BEIR VII
methodology19:
LARðD; e; aÞ ¼
X100
a
MðD; e; aÞ SðaÞ
SðeÞ;
where M (D ,e, a) is the excess absolute risk for breast
cancer, and S(a)/S(e) is the probability of the patient
surviving from their age at exposure to their attained age.
The LAR model was chosen as it includes age at
exposure, a latency period, attained age since exposure,
gender and organ-specific parameters. The contralateral
breast LAR was assessed for women exposed at the age of
50 years and for the following protocols: treatment plus
daily MV-CT imaging (25 scans), treatment plus daily




The mean patient age was 57.8 years (standard
deviation  8.8 years). Mean volume of the primary
breast was 1006.5 cm3 (range, 215.3–2144.5 cm3). All
patients received a treatment dose of 50 Gy in 25
fractions. The range of differences in breast volume is
shown in Figure 1. The mean OAR dose and range for
daily imaging with the MV-CT, MV-EPI and MV-CBCT
for the 30 patients are displayed in Table 1. The mean
cumulative dose to OAR from treatment with no imaging
and treatment plus daily image verification for the three
imaging modalities are displayed in Figure 2 for the 30
patients. The highest cumulative dose was from the
prescribed treatment plus daily MV-CBCT, followed by
MV-EPI and MV-CT for all OAR. On average, a single
MV-CBCT, MV-EPI and MV-CT scan contributed ~10%,
3% and 1%, respectively, in proportion to the total
treatment dose for the contralateral breast. A similar
trend was found for contralateral lung, spinal cord and
heart.
Primary breast volume and BMI
A positive Pearson correlation (r) was established for
primary breast volume and BMI, namely, r = 0.608. The
primary breast volume inversely correlated with the
contralateral breast dose for all three imaging modalities
with r values of 0.399, 0.747 and 0.655 for the MV-
CT, MV-EPI and MV-CBCT, respectively, indicating that
the absorbed dose to the contralateral breast decreases as
the breast volume increases. Pearson’s r value is a
descriptor of the degree of linear association between
primary breast volume and dose. When the value is
approaching zero, there is no correlation, but as it
approaches 1 or +1 there is a strong negative or
positive relationship between primary breast volume and
dose. The correlation for MV-CT was weak but
statistically significant at the 0.05 level (Fig. 3). The
Pearson correlation value for primary breast volume
versus OAR dose for the three imaging modalities is
displayed in Table 2. There is strong correlation between
primary breast volume and all OAR doses for MV-CBCT,
and all but heart for MV-EPI. Only contralateral breast
and heart doses correlated with primary breast volume
for MV-CT. The correlation between BMI and OAR dose
is outlined in Table 3 with similar results.
Figure 1. The range of breast volume for the 30 patients.
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Secondary cancer risk
The baseline probability of a woman developing breast
cancer over her lifetime is 12.7% based on the
Surveillance, Epidemiology, and End Results (SEER)
breast cancer incidence rates.22 The LAR for the patient
with the smallest breast volume (215.3 cm3) for MV-CT,
MV-EPI and MV-CBCT was 0.65%, 0.74% and 1.46%
respectively. In contrast, the LAR for the patient with the
largest breast volume (2144.5 cm3) was 0.36%, 0.48%
and 0.66% for MV-CT, MV-EPI and MV-CBCT
respectively. The trend line showing the LAR of
developing secondary cancer risk in the contralateral
breast with respect to primary breast volume is displayed
in Figure 4. The displayed risk is the treatment plus daily
imaging risk for women exposed at the age of 50 years.
As the primary breast volume increases, the likelihood of
a patient developing secondary cancer to the contralateral
breast decreases. The trend line for MV-CBCT suggests
that the LAR of developing an induced lesion in the
contralateral breast is greater than that for MV-CT and
MV-EPI.
Discussion
Image guidance has previously been shown to reduce
setup errors during breast radiotherapy.6–8 The additional
dose from MV-CT, MV-EPI and MV-CBCT acquired for
Table 1. Mean organ at risk dose (Gy) and range for the 30 patients from daily imaging (25 scans) with the MV-CT, MV-EPI and MV-CBCT.
Organ at risk
Mean dose in Gray (range)
MV-CT MV-EPI MV-CBCT
Contralateral breast 0.11 (0.08–0.13) 0.22 (0.16–0.34) 1.79 (1.53–2.13)
Ipsilateral lung 0.08 (0.07–0.12) 0.84 (0.64–1.53) 1.49 (1.12–1.81)
Contralateral lung 0.08 (0.07–0.12) 0.33 (0.22–0.42) 1.50 (1.02–1.81)
Spinal cord 0.08 (0.07–0.12) 0.45 (0.24–0.57) 1.18 (0.64–1.54)
Heart 0.12 (0.10–0.14) 0.55 (0.39–0.92) 1.70 (1.47–1.93)
MV-CT, megavoltage computed tomography; MV-EPI, megavoltage electronic portal image; MV-CBCT, megavoltage cone-beam computed
tomography.
Figure 2. Cumulative (mean) organs at risk dose from treatment alone, and treatment plus daily imaging from megavoltage computed
tomography (MV-CT), megavoltage electronic portal image (MV-EPI) and megavoltage cone-beam computed tomography (MV-CBCT).
ª 2015 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of
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breast radiotherapy verification has been presented in this
study for patients with a range of breast sizes.
This study found that the highest dose was from
MV-CBCT, followed by MV-EPI and MV-CT to all
OARs. This is attributed to the MV-CBCT geometry
resulting in more scatter and as a consequence increased
patient dose in comparison with the MV-CT.
Furthermore, MV-CBCT utilises higher beam energy
(6 MV) compared to the MV-CT (3.5 MV). MV-CBCT
dose was also higher than MV-EPI even though both
modalities used 6 MV. This is because the field of view
for a single projection of MV-CBCT has a standard field




R P value R P value R P value
Contralateral breast 0.399 0.029* 0.747 0.000** 0.655 0.000**
Ipsilateral lung 0.036 0.851 0.705 0.000** 0.752 0.000**
Contralateral lung 0.087 0.647 0.712 0.000** 0.663 0.000**
Spinal cord 0.223 0.237 0.510 0.004** 0.696 0.000**
Heart 0.512 0.004** 0.307 0.099 0.860 0.000**
MV-CT, megavoltage computed tomography; MV-EPI, megavoltage electronic portal image; MV-CBCT, megavoltage cone-beam computed
tomography.
*Correlation is significant at the 0.05 level (two-tailed).
**Correlation is significant at the 0.01 level (two-tailed).
(a) (b) (c)
Figure 3. Scatter-plot correlation of primary breast volume versus contralateral breast dose from (A) megavoltage CT, (B) megavoltage electronic
portal image and (C) megavoltage cone-beam CT.




R P value R P value R P value
Contralateral breast 0.262 0.161 0.674 0.000** 0.598 0.000**
Ipsilateral lung 0.089 0.639 0.639 0.000** 0.657 0.000**
Contralateral lung 0.177 0.348 0.660 0.000** 0.602 0.000**
Spinal cord 0.297 0.111 0.239 0.204 0.598 0.000**
Heart 0.603 0.000** 0.329 0.075 0.793 0.000**
MV-CT, megavoltage computed tomography; MV-EPI, megavoltage electronic portal image; MV-CBCT, megavoltage cone-beam computed
tomography.
**Correlation is significant at the 0.01 level (two-tailed).
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width of 27.4 cm, whereas the field size for MV-EPI was
kept to the minimum for each patient resulting in lower
dose to OARs.
Previous treatment planning simulation studies have
reported on the dose delivered to the chest region for the
MV-EPI,13 MV-CBCT13,15 and MV-CT.16 The organ dose
trends reported by Peng et al.13 are in agreement with the
results of this study. With the exception of the heart,
lower organ dose values for an 8 MU MV-CBCT were
reported, 0.8 Gy, 0.82 Gy and 1.68 Gy for the
contralateral breast, lungs and heart (25 scans)
respectively. Differences are attributed to the variable field
lengths utilised in this study and the smaller field width
utilised by Peng et al.13 For the same scan parameters,
VanAntwerp et al.15 reported comparable mean
MV-CBCT organ dose values, 1.65, 1.18 and 1.73 Gy (25
scans) for the lungs, spinal canal and heart respectively.
Shah et al.16 reported higher MV-CT organ doses, 0.27,
0.29 and 0.38 Gy for the contralateral breast, lungs and
heart respectively. This dose difference is attributed to
only one patient image set being assessed by Shah et al.16
The range of organ doses identified in this study indicates
that the single mean dose and standard deviation
reported in other treatment planning simulation studies
are not representative of all patients.
Previous phantom studies have reported lower organ
doses in comparison with this study for MV-EPI and
MV-CBCT.9,10 However, a phantom MV-CT dosimetry
study14 reported higher organ doses compared to this
study. Similar to above, this demonstrates that phantom
studies are not always a true representative of patient size
and doses received by individual patients.
The accuracy of the calculated doses has been
investigated by previous studies. Gayou et al.23
investigated patient dose from a MV-CBCT with the XiO
treatment planning system as well as with a range of
dosimeters in anthropomorphic and cylindrical
phantoms. The difference between the calculated and
measured doses was found to be less than 5% for the
anthropomorphic phantom. Shah et al.15 commissioned
and validated the MV-CT model utilised in this study
finding the computed doses to be within 5% of doses
measured in an anthropomorphic phantom. Joosten
et al.24 investigated the peripheral dose calculation
accuracy of the XiO treatment planning system and
found that at 10 cm from the field edge of a
20 9 20 cm2 open beam, the treatment planning system
underestimated the dose by a maximum of 31%.
This study demonstrated that for treatment plus daily
imaging protocols the primary breast size does affect
OAR dose. The data indicated an inverse linear
correlation between primary breast size and OAR doses,
indicating that as breast size is increased, OAR dose
decreases. A correlation between BMI and OAR dose
was significant for the contralateral breast, and lungs for
the MV-EPI, all OAR for the MV-CBCT, and only the
heart for the MV-CT. A weak relationship between BMI
and MV-CBCT dose for 27 thoracic patients was
determined by VanAntwerp et al.15; however, no
statistical analysis of this relationship was performed. In
this study, a more reliable correlation can be suggested
between breast size and organ doses, regardless of
imaging modality.
The increased likelihood of developing a second cancer
in the contralateral breast after breast radiotherapy with
daily image verification for three image modalities was
estimated. LAR was found to decrease with increasing
breast volume and was highest for MV-CBCT imaging.
This is attributed to the contralateral breast dose
decreasing with increasing breast volume and the
contralateral breast dose being greatest for the MV-CBCT.
Breast cancer survivors have an 18% higher risk of
developing a subsequent cancer.25 Younger patients (less
than 45 years) have been found to be at a greater risk of
developing a second contralateral breast cancer.26–28
There is conflicting data for women aged 50 years or
older.26–30 Five years post treatment, a SEER cancer
registry study26 observed that the relative risk of
contralateral breast cancer was 1.30, 0.98 and 1.14 for
those diagnosed at less than 40, 50–59 years and 60 years
and above respectively. However, a meta-analysis of 70
randomised breast radiotherapy treatment studies27 found
women diagnosed at the age of 50 years and above had a
significant risk of developing contralateral breast cancer,
P = 0.002 (ratio of rates 1.25).
This study utilised standard imaging parameters with
field length adjusted according to the patient’s breast size as
it is common in clinical practice. This study demonstrated
Figure 4. Trendline showing the lifetime attributable risk (LAR) of
developing secondary cancer in the contralateral breast relative to
breast volume for treatment alone and treatment plus daily imaging
with the megavoltage computed tomography (MV-CT), megavoltage
electronic portal image (MV-EPI) and megavoltage cone-beam CT
(MV-CBCT).
V. Batumalai et al. Imaging Dose in Breast Radiotherapy
ª 2015 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of
Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology
37
the resulting contralateral breast dose variation due to the
changes in patient anatomy particularly the primary breast
size. Although not assessed in this study, it is likely that for
standard imaging parameters image quality will also vary
with patient anatomical changes.15 The AAPM Task Group
7531 have recommended that strategies for reducing the
imaging dose and volume of exposed anatomy be pursued
wherever possible, in line with the ALARA (as low as
reasonably achievable) principle. Thus, variation of
standard imaging parameters on a patient by patient basis
could be considered; however, it should also be noted that
dose variation between imaging modalities is greater than
dose variation between individual patients imaged on single
imaging modality.
Conclusions
The range of imaging doses to surrounding OAR for
breast radiotherapy patients with different breast sizes has
been presented in this study for MV-CT, MV-EPI and
MV-CBCT. Imaging dose to the contralateral breast was
inversely correlated with primary breast volume for all
three imaging modalities. This study showed that for
breast patients, imaging dose to OAR depends on
imaging modality and treated breast size. When
considering the use of daily imaging during breast
radiotherapy treatment, the patient’s breast size should be
taken into account. The clinical benefit of daily imaging
should be weighed against the additional risk, as adoption
of daily imaging without clinical evidence may have
increased risk on patients.
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